차입 증가 → 이자부담 → 수익성 악화
Critical부채가 +27.1% 늘며 이자보상배율이 -654.3x에서 -1048.2x로 하락했다. ROE도 -18.8%에서 -28.1%로 낮아져 차입 부담이 수익성을 누르고 있다.
Evidence
부채 YoY +27.1%이자보상배율 -654.3x→-1048.2xROE -18.8%→-28.1%
GH Research
GHRS · Nasdaq$28.23+1.11%
2026-09-04 closeGH Research last closed at $28.23 (+1.11%) on 2026-09-04. Listed on Nasdaq; price, financials and dividends update daily after market close.
Loading chart…
Close
Market Leader RS 95 · top 5%
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p
Every new-high-plus-volume pick we actually published (US market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
A
Overall: 건강관리 114/745 · top 15%
Factor composite · relative position in sector
PER — · PBR 9.79 — own-history percentile 67/100 · 15/100
Open self-history band
PER67/100
PBR15/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 21.67
Distress
Grey
Safe
- Altman Z''
- 21.67
- Beneish M-Score
- —
- Sloan accrual
- 1.77%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
1/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score1/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Connections
AI-extracted related companies · for reference
Competitors
J&JPrice comovement r=-0.02 (1 year)Eli LillyPrice comovement r=-0.01 (1 year)AbbViePrice comovement r=0.12 (1 year)TakedaAstraZenecaBristol Myers SquibbPrice comovement r=0.08 (1 year)Neurocrine BiosciencesPrice comovement r=0.07 (1 year)Sage TherapeuticsBiogenPrice comovement r=0.05 (1 year)LundbeckAlkermesPrice comovement r=0.04 (1 year)Compass Pathways
Same theme
Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
About GH Research
- What technical signals does GH Research (GHRS) have?
- GH Research current technical signals: no active technical signal.
- Is GH Research a cup-and-handle pattern?
- No. GH Research has no valid cup-and-handle signal right now.
- What are GH Research's financials and valuation?
- GH Research's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy